SANA (MVD1)

SANA (MVD1) attracts interest for weight loss while keeping an appetite. One SANA/BAM15 user reported a falling scale, then later stopped after lethargy; a separate SANA experiment describes little early effect. These accounts cannot establish SANA’s benefit or safety.

What SANA is

• SANA and MVD1 name the same small molecule. The chemical name is 5-(2-nitroethenyl)salicylic acid, a salicylate derivative rather than a peptide. MVD1 is its clinical-development code. Official context
• The appeal is spending more energy without losing interest in food. The combination poster wanted an alternative to appetite suppression. That preference explains the interest; it does not demonstrate which ingredient changed the scale. Personal report
• Related to thermogenesis, but different from BAM15. Thermogenesis means producing heat. SANA’s animal research points to creatine-dependent energy use in fat tissue, not direct mitochondrial uncoupling; the BAM15 combination therefore joins distinct experimental compounds. Official context

What people report and hope for

• A smaller waist with hunger preserved. The combined-use poster reported 6.7 lb less on the scale by week three and looser clothing, while still enjoying meals. These were self-observations, not measured fat loss. Personal report
• The separate SANA log has no final result yet. N=1 After 40 is looking for visible leanness, but the inspected page does not report a completed SANA body-composition result. Its early lack of sensation belongs beside the favorable combination account. Personal report

Doses people discuss

• 250 mg SANA plus 70 mg BAM15 per capsule. These are the combination poster’s labeled oral amounts. Daily capsule count is not explicit; neither number is a verified SANA-only daily dose. Personal report
• One oral log describes 50, 100, 200, 400 and 800 mg/day. These are successive stages in one experiment, not a community range or escalation guide. The last stage is 400 mg after waking plus 400 mg before sleep; the kidney caution below is especially relevant. Personal report

Half-life

• 1.6–2.0 hours is a secondary claim attributed to the human trial. The Reptides comparison gives this figure for oral SANA. The primary numerical table was not accessible in this review, so it remains an attributed claim, not a verified clearance clock or dosing interval. Reptides research wiki

When people notice a change

• The combination account noticed warmth near the end of week one. The first days were uneventful; scale change followed around week two. Hot weather also affected warmth. This is a repeated-use timeline, not single-dose onset. Personal report
• Little early sensation in the separate SANA log. The author reported no noticeable effect at 50 mg/day and little thermogenic effect at 100 mg/day. This does not prove either efficacy or failure at later stages. Personal report

How long effects last

• A dependable felt duration is unknown. Neither account establishes an hours-long benefit window after one dose or persistence after stopping. Weeks of observations describe a course, not a drug’s half-life. Personal report Personal report

Courses and breaks

• The combination poster later stopped. An intended two-month supply is not evidence of two months completed. No clear restart or break length is established. Personal report
• The separate log remains open-ended. It began August 14, 2026 and describes a further change September 22. No completed cycle or tested time-off rule is provided. Personal report

What deserves caution

• Kidney injury occurred in the human trial. Two of the three participants given a single 800 mg dose developed reversible kidney-tubule injury, with protein and glucose in urine. Reversal does not establish repeated-use safety; the personal log’s split 800 mg/day is a different exposure. Official context Personal report
• Headache and soft stools were reported in the trial. They were among the possibly drug-related events. Short supervised observation cannot establish long-term safety or the safety of combining SANA with BAM15. Official context
• A seller’s molecule name does not authenticate a capsule. Kimera uses the SANA/MVD1 identity, but neither a catalog description nor an online testimonial verifies what a particular product contains. A clinical-study formulation cannot certify a seller’s product. Community guide Official context

What the community accounts add

• The same author’s later update changes the picture. The combination poster initially described ordinary energy and unchanged sleep, then later attributed lethargy to BAM15 and planned SANA alone. That explanation is untested; the planned switch is not a completed SANA-only result. Personal report
• A change from CL-316243 is a personal comparison. N=1 After 40 says CL was stopped before SANA and describes judging the new experiment against a prior visual result. Sequential experiments with a wider stack are not a controlled comparison. Personal report
• Some forum members see little reason to move beyond GLP-1 drugs. In the MESO discussion, one says GLP-1 drugs already work for them; another wants a different pathway. The opening post discloses an AI-assisted research summary, not personal use, and speculation about protecting the liver from steroids remains unsupported. MESO-Rx forum
• Heat, appetite and the scale answer different questions. Feeling warm does not measure fat loss, and a lower scale reading cannot separate fat from water or other changes. Useful accounts record both wanted changes and reasons to stop; they do not establish a typical response. Personal report Personal report

What the early human study adds

• A small safety trial found an exploratory weight signal. In the Phase 1A/B trial, repeated oral doses were 100, 150 or 200 mg every 12 hours for 15 days: 200, 300 or 400 mg/day. Six people in the highest group lost roughly 3%; the plotted placebo weight comparison had three. Weight was exploratory in a safety-focused study, not confirmed efficacy. Official context